Allos Settles Investor Suit Over $686M AMAG Tie-Up

Law360, New York (October 13, 2011, 9:08 PM EDT) -- Allos Therapeutics Inc. said Thursday that it had settled a shareholder class action over the company's planned $686 million all-stock merger with AMAG Pharmaceuticals Inc., paving the way for the deal's completion.

Under the terms of the settlement, Allos will file a report "amending and supplementing certain disclosure in the joint proxy statement/prospectus filed by Allos in connection with the merger."

The company didn't reveal the nature of those updates, or any other terms of the settlement, which is contingent on several factors, including the merger's...
To view the full article, register now.